• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CMB 1.28% 38.5¢

CAMBIUM BIO LIMITED

Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage... Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
CMB 04/09/24 1 599
04/09/24 Last post  Biotechasx Comments Created with Sketch.  1  Views Created with Sketch.  599 
CMB 30/08/24 0 95
30/08/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  95 
CMB 30/08/24 0 157
30/08/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  157 
CMB
What it Take to be a CORPORATE JOKER
26/08/24 7 3.4K
26/08/24 Last post  pakkham Comments Created with Sketch.  7  Views Created with Sketch.  3.4K 
CMB 31/07/24 0 124
31/07/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  124 
CMB 31/07/24 0 106
31/07/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  106 
CMB 31/07/24 0 192
31/07/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  192 
CMB 19/07/24 0 241
19/07/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  241 

See All Discussions arrow Created with Sketch.

Timeline

CEO Revised Engagement Agreement Terms
30 Aug 14:47
 
Appendix 4G and Corporate Governance Statement
30 Aug 14:28
 
Cambium 4E and Annual Report
30 Aug 14:27
 
Change in substantial holding-Apex
31 Jul 10:45
 
Change in substantial holding-Treasure
31 Jul 10:44
 
Quarterly Activities/Appendix 4C Cash Flow Report
31 Jul 10:37
 
View More arrow Created with Sketch.
(20min delay)
Last
38.5¢
Change
-0.005(1.28%)
Mkt cap ! $4.593M
Open High Low Value Volume
38.5¢ 38.5¢ 38.5¢ $1.548K 4.02K

Buyers (Bids)

No. Vol. Price($)
1 2000 31.0¢
 

Sellers (Offers)

Price($) Vol. No.
39.0¢ 4627 2
View Market Depth
Last trade - 12.28pm 27/09/2024 (20 minute delay) ?
CMB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.